Can tirzepatide (Mounjaro) cause vertigo?

Can Mounjaro (Tirzepatide) Cause Vertigo?

Vertigo is not listed as a recognized adverse effect in the FDA drug label for Mounjaro, though dizziness—which can be confused with vertigo—is documented as a symptom of hypoglycemia, a known side effect of the medication. 1

Understanding the Distinction

The FDA label for Mounjaro specifically lists dizziness or light-headedness as a sign of low blood sugar (hypoglycemia), particularly when tirzepatide is used with insulin or sulfonylureas 1. However, true vertigo (a sensation of spinning or rotation) is not mentioned among the documented adverse effects in the official prescribing information 1.

Emerging Evidence on Vestibular Effects

Recent research suggests a potential association between GLP-1 receptor agonists and vestibular disorders:

• A 2025 real-world cohort study found tirzepatide users had an increased risk of vestibular disorders compared to matched controls, with hazard ratios ranging from 3.19 at 6 months to 4.55 at 3 years 2
• The absolute incidence remained low (0.10% at 6 months to 0.19% at 3 years) 2
• A 2025 meta-analysis of 12 RCTs involving 10,615 patients found tirzepatide significantly increased the risk of dizziness (RR 1.64,95% CI 1.04 to 2.57), with higher risk in patients aged ≤60 years 3

It's critical to distinguish between dizziness (a vague sensation of spatial disorientation) and true vertigo (spinning sensation). The evidence predominantly describes "dizziness" rather than vertigo specifically.

Clinical Considerations

When Dizziness Occurs with Tirzepatide:

1. First, rule out hypoglycemia - Check blood glucose, especially if the patient is on insulin or sulfonylureas 1
2. Assess for dehydration - Gastrointestinal side effects (nausea, vomiting, diarrhea) can cause fluid loss leading to orthostatic symptoms 1
3. Consider vestibular evaluation - If true rotational vertigo is present and other causes are excluded 2

Common Pitfalls:

• Don't assume all "dizziness" is vertigo - Most patients use "dizzy" to describe lightheadedness, presyncope, or imbalance rather than true spinning sensation
• Don't overlook hypoglycemia - This is the most common and clinically significant cause of dizziness with tirzepatide, particularly with dose escalation 1
• Don't ignore dehydration - The most common side effects are gastrointestinal, occurring during dose escalation, and can lead to volume depletion 4

Practical Management Algorithm

If a patient on tirzepatide reports "dizziness":

1. Clarify the symptom: Is it spinning (vertigo), lightheadedness (presyncope), or imbalance?
2. Check blood glucose immediately if available
3. Review concomitant medications (insulin, sulfonylureas)
4. Assess hydration status and recent GI symptoms
5. If true vertigo with spinning sensation and no other cause identified, consider vestibular evaluation and potential medication contribution 2

The evidence suggests that while vestibular symptoms may occur, they are uncommon, and more typical causes of dizziness (hypoglycemia, dehydration) should be systematically excluded first.